Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not carry on? Our survival plan calls for quaffing a cup or three of delicious stimulation. Our choice today is wild mountain blueberry. As always, you are welcome to join us. Remember — no prescription is required. So time to get cracking. After all, there are meetings, phone calls, and deadlines awaiting. To help you along, we have gathered a menu of tidbits. We hope you find them helpful. Meanwhile, have a wonderful day and do stay in touch …
The Medicines Company (MDCO) plans to restructure and lay off more than 85 percent of its workforce, MarketWatch tells us. The drug maker, which currently has 410 employees, plans to reduce headcount to fewer than 60 people and carry out most of the restructuring in the next 45 days. The company plans to announce a divestiture of its infectious diseases business by the end of the year.
GlaxoSmithKline (GSK) chief executive officer Emma Walmsley says that she will look at the consumer health business that Pfizer (PFE) may sell, but that her top priority is boosting the pharma pipeline, Reuters confides. At the same time, she says Glaxo will also look carefully at German Merck (MRK) consumer assets and is happy to continue to work with Novartis (NVS) on consumer health or take over the Novartis stake if a sale is possible to arrange.
About the Author Reprints
